Home › Funds › Viking Global Investors › ROIV

Viking Global Investors position in ROIV

ROIVANT SCIENCES LTD · Health Care

Viking Global Investors reported holding 6,757,326 shares of ROIV (ROIVANT SCIENCES LTD) in its Q3 2026 13F filing — a position valued at US$247.1M, representing 0.76% of its reported portfolio and ranking #46 among its reported holdings. Viking Global Investors has disclosed ROIV holdings in 20 of the last 20 reported quarters, going back to Q4 2021.

Latest position (Q3 2026)6.76M sh
Reported value held$247.12M
Portfolio Weight0.76%
First reportedQ4 2021
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Viking Global Investors's ROIV position evolved

Viking Global Investors first disclosed a stake in ROIV in Q4 2021 at 88,238,700 shares (US$889.4M). Across 20 filings, Viking Global Investors increased the stake 2 time(s), trimmed it 10 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 6,757,326 shares valued at US$247.1M — an increase of 485,859 shares quarter over quarter.. Notable position changes include a 26% trim in Q2 2025 (shares rose 34% over the following quarter), a 31% trim in Q3 2025 (shares rose 43% over the following quarter), a 73% trim in Q4 2025 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2021 88.24M $889.45M New
Q1 2022 88.24M $435.90M Hold
Q2 2022 88.24M $359.13M Hold
Q3 2022 88.24M $284.13M Hold
Q4 2022 88.24M $705.03M Hold
Q1 2023 88.24M $651.20M Hold
Q2 2023 75.24M $758.41M Reduce
Q3 2023 73.43M $857.71M Reduce
Q4 2023 69.37M $779.01M Reduce
Q1 2024 69.37M $731.15M Hold
Q2 2024 69.16M $730.98M Hold
Q3 2024 54.10M $624.30M Reduce
Q4 2024 47.81M $565.59M Reduce
Q1 2025 46.01M $464.28M Reduce
Q2 2025 34.24M $385.86M Reduce
Q3 2025 23.59M $356.99M Reduce
Q4 2025 6.44M $139.82M Reduce
Q1 2026 6.65M $184.27M Add
Q2 2026 6.27M $221.95M Reduce
Q3 2026 6.76M $247.12M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ROIV and 13F data

ROIV (ROIVANT SCIENCES LTD) is a Health Care company. 53 other funds we track also report a position in ROIV — the largest reported positions include QVT Financial LP (US$867.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$795.2M), Farallon Capital Management (US$795.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ROIV

All ROIV fund holders →

FAQ

How long has Viking Global Investors held ROIV?

Viking Global Investors has disclosed ROIV holdings in 20 of the last 20 reported quarters, going back to Q4 2021.

What is Viking Global Investors's current position in ROIV?

As of Q3 2026, Viking Global Investors holds 6.76M shares of ROIV (ROIVANT SCIENCES LTD), valued at $247.12M, representing 0.76% of its reported portfolio and ranking #46.

Has Viking Global Investors been buying or selling ROIV?

In the latest 13F filing (Q3 2026), Viking Global Investors increased its position in ROIV.

Which other funds hold ROIV?

Other major institutional holders of ROIV include QVT Financial LP, FARALLON CAPITAL MANAGEMENT, L.L.C., Farallon Capital Management, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.